Success Metrics

Active Trials
2(20%)

Phase Distribution

Ph phase_2
7
70%
Ph phase_1
2
20%
Ph phase_3
1
10%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Other(8)

Detailed Status

unknown8
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
Phase 31 (10.0%)

Trials by Status

active_not_recruiting110%
unknown880%
recruiting110%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruitingphase_1

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

NCT04492488
recruitingphase_3

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

NCT05754853
unknownphase_2

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT04924699
unknownphase_2

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

NCT05263869
unknownphase_2

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

NCT04742153
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04492488Phase 1

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active Not Recruiting
NCT05754853Phase 3

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting
NCT04924699Phase 2

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Unknown
NCT05263869Phase 2

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Unknown
NCT04742153Phase 2

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Unknown
NCT05141747Phase 2

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Unknown
NCT04839510Phase 2

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Unknown
NCT04837508Phase 2

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Unknown
NCT04941339Phase 1

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Unknown
NCT05141786Phase 2

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10